PDCD1 and non-small cell lung carcinoma: Fan et al. found that in NSCLC treated with anti-PD-1 antibody, miR-93, miR-138-5p, miR-200, miR-27a, miR-424, miR-34a, miR-28, miR-106b, miR-193a-3p, and miR-181a were significantly upregulated in responders versus non-responders (Fan et al., 2020).